Premium
The VITA Project: C677T mutation in the methylene‐tetrahydrofolate reductase gene and risk of venous thromboembolism
Author(s) -
TOSETTO ALBERTO,
MISSIAGLIA EDOARDO,
FREZZATO MAURIZIO,
RODEGHIERO FRANCESCO
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.1422957.x
Subject(s) - methylenetetrahydrofolate reductase , medicine , venous thromboembolism , mutation , reductase , gene , genetics , gastroenterology , biology , biochemistry , enzyme , allele , thrombosis
We evaluated the hypothesis that a common polymorphism of the methylenetetrahydrofolate reductase gene (C677T), which results in increased levels of plasma homocysteine, may be a putative risk factor for venous thromboembolism (VT). Sixty‐five cases of VT and 130 controls, both identified within the framework of an epidemiologic survey on thrombophilia, the Vicenza Thrombophilia and Arteriosclerosis (VITA) Project, were genotyped for the mutation. No increased risk of VT was found in carriers of the mutation. We conclude that screening for the C677T mutation of the methylenetetrahydrofolate reductase gene should not be recommended in unselected patients with VT.